YH-306

An anticancer agent, reduces TGF-beta-induced transcriptional activity by 72.4% in a reporter assay using HaCaT cells at 1 µM, inhibits the proliferation of PC-9, H1299, and A549 cells (IC50s = 5.87, 8.07, and 7.9 µM, respectively), decreases migration of H1299 cells in a wound healing assay at 0.1, 0.5, or 1 µM, inhibits actin polymerization in HT-29 cells at 50 µM, inhibits fibronectin-induced increases in the levels of MMP-2, MMP-9, and phosphorylated FAK, PI3K, and ERK in CT26 cells at 50 µM, decreases tumor volume without reducing body weight in an A549 mouse xenograft model at 5 mg/kg per day, reduces tumor growth and the number of hepatic metastases in a CT26-luc colon cancer mouse xenograft model with hepatic metastases at 50 mg/kg per day. Formulation: A solid. InChI: InChI=1S/C19H18N2O2/c22-14-7-5-13(6-8-14)11-19(23)21-10-9-16-15-3-1-2-4-17(15)20-18(16)12-21/h1-8,20,22H,9-12H2. InChIKey: WFTJZQLEQGPZBC-UHFFFAOYSA-N. SMILES: O=C(CC1=CC=C(C=C1)O)N2CC3=C(CC2)C4=C(C=CC=C4)N3